NO20060851L - Kombinasjoner av en katepsin K-inhibitor og et bisfosfonat ved behandling av benmetastase, tumorvekst og tumorindusert bentap - Google Patents

Kombinasjoner av en katepsin K-inhibitor og et bisfosfonat ved behandling av benmetastase, tumorvekst og tumorindusert bentap

Info

Publication number
NO20060851L
NO20060851L NO20060851A NO20060851A NO20060851L NO 20060851 L NO20060851 L NO 20060851L NO 20060851 A NO20060851 A NO 20060851A NO 20060851 A NO20060851 A NO 20060851A NO 20060851 L NO20060851 L NO 20060851L
Authority
NO
Norway
Prior art keywords
tumor
cathepsin
bone loss
induced
bisphosphonate
Prior art date
Application number
NO20060851A
Other languages
English (en)
Norwegian (no)
Inventor
Johann Zimmermann
Carsten Goessl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060851(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20060851L publication Critical patent/NO20060851L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20060851A 2003-07-21 2006-02-21 Kombinasjoner av en katepsin K-inhibitor og et bisfosfonat ved behandling av benmetastase, tumorvekst og tumorindusert bentap NO20060851L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48892503P 2003-07-21 2003-07-21
PCT/EP2004/008107 WO2005014006A1 (fr) 2003-07-21 2004-07-20 Combinaisons d'un inhibiteur de cathepsine k et d'un bisphophonate utilisees dans le traitement des metastases osseuses, de la croissance des tumeurs et de la perte osseuse induite par une tumeur

Publications (1)

Publication Number Publication Date
NO20060851L true NO20060851L (no) 2006-04-21

Family

ID=34135094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060851A NO20060851L (no) 2003-07-21 2006-02-21 Kombinasjoner av en katepsin K-inhibitor og et bisfosfonat ved behandling av benmetastase, tumorvekst og tumorindusert bentap

Country Status (21)

Country Link
US (1) US20060281714A1 (fr)
EP (1) EP1651238A1 (fr)
JP (1) JP2006528151A (fr)
KR (1) KR20060037382A (fr)
CN (1) CN100406016C (fr)
AR (1) AR045728A1 (fr)
AU (1) AU2004262903B2 (fr)
BR (1) BRPI0412769A (fr)
CA (1) CA2532948A1 (fr)
CO (1) CO5680441A2 (fr)
EC (1) ECSP066293A (fr)
IL (1) IL172913A0 (fr)
IS (1) IS8311A (fr)
MA (1) MA27925A1 (fr)
MX (1) MXPA06000790A (fr)
NO (1) NO20060851L (fr)
PE (1) PE20050328A1 (fr)
RU (1) RU2006105100A (fr)
TN (1) TNSN06021A1 (fr)
TW (1) TW200510436A (fr)
WO (1) WO2005014006A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545723A1 (fr) * 2003-11-19 2005-06-02 Novartis Ag Utilisation d'inhibiteurs de cathepsine k dans des maladies de la perte osseuse severe
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
JP2009509966A (ja) * 2005-09-26 2009-03-12 ノバルティス アクチエンゲゼルシャフト 骨転移に関連した分子マーカー
US20100331545A1 (en) * 2007-10-24 2010-12-30 Nippon Chemiphar Co., Ltd. Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
EP3426674A4 (fr) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. Composés céto-amides cycliques utilisés en tant que modulateurs de la calpaïne, et leurs procédés de production et d'utilisation
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018064119A1 (fr) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Modulateurs de calpain et leurs utilisations thérapeutiques
EP3813726A1 (fr) 2018-06-27 2021-05-05 Cirlo GmbH Implants pour recruter et retirer des cellules tumorales circulantes
US20230046007A1 (en) 2019-12-17 2023-02-16 Cirlo Gmbh Tubular shaped elongated catheter device assemblies for interacting with components of bodily fluids, method for recovering cells, cell aggregates and exosomes from a tubular shaped elongated catheter device and smart tubular shaped elongated catheter device assemblies for monitoring interaction with components of bodily fluids
US20250281518A1 (en) * 2022-04-27 2025-09-11 The Regents Of The University Of California Methods and agents for preventing skeletal aging, osteoporosis and obesity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501969A (en) * 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
US6544767B1 (en) * 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
WO2000006169A1 (fr) * 1998-07-29 2000-02-10 Merck & Co., Inc. Antagonistes des recepteurs de l'integrine
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
HK1039110A1 (zh) * 1999-03-15 2002-04-12 Axys Pharmaceuticals, Inc. 以新颖的合成物及组分作为蛋白酶抑制剂
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
WO2003041649A2 (fr) * 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Derives cyanoalkylamino utilises comme inhibiteurs de la protease

Also Published As

Publication number Publication date
PE20050328A1 (es) 2005-06-16
RU2006105100A (ru) 2007-09-20
CN1826124A (zh) 2006-08-30
BRPI0412769A (pt) 2006-09-26
IS8311A (is) 2006-02-17
AR045728A1 (es) 2005-11-09
ECSP066293A (es) 2006-07-28
AU2004262903A1 (en) 2005-02-17
CN100406016C (zh) 2008-07-30
MA27925A1 (fr) 2006-06-01
MXPA06000790A (es) 2006-04-07
EP1651238A1 (fr) 2006-05-03
CO5680441A2 (es) 2006-09-29
US20060281714A1 (en) 2006-12-14
AU2004262903B2 (en) 2007-08-23
CA2532948A1 (fr) 2005-02-17
TW200510436A (en) 2005-03-16
JP2006528151A (ja) 2006-12-14
IL172913A0 (en) 2006-06-11
TNSN06021A1 (en) 2007-10-03
KR20060037382A (ko) 2006-05-03
WO2005014006A1 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
NO20071077L (no) Fosfonatanaloger til HIV-inhibitorforbindelser
CY1107927T1 (el) Ενωσεις φωσφονικου
IS2549B (is) Kaþepsín systein próteasa hindrar
NO20070866L (no) Antivirale forbindelser.
NO20060851L (no) Kombinasjoner av en katepsin K-inhibitor og et bisfosfonat ved behandling av benmetastase, tumorvekst og tumorindusert bentap
MY142045A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
NO20090783L (no) Pyrimidonforbindelser som inhibitorer av GSK-3
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
WO2003059898A3 (fr) Analogues d'eponemycine et d'epoxomicine et leurs utilisations
TW200631576A (en) Cathepsin cysteine protease inhibitors
DK1443967T3 (da) Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor
WO2004050023A3 (fr) Traitement de maladies et d'etats a mediation de phosphorylation accrue
PT1831209E (pt) Inibidores de fosfatases cdc25
EP1902031A4 (fr) Inhibiteurs de cystéine protéases de type cathepsine
WO2004060878A3 (fr) Inhibiteurs de phosphatases
DK1443942T3 (da) Farmaceutisk sammensætning til anvendelse ved behandling af maligniteter omfattende en kombination af et bisphosphonat, en COX-2 inhibitor og en taxol
JP2005506371A5 (fr)
DK1814879T3 (da) Derivater af 4,7-dioxobenzothiazol-2-caboxamider, fremgangsmåde til fremstilling deraf og terapeutiske anvendelser af samme
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
WO2009024631A9 (fr) Combinaisons thérapeutiques pour le traitement des métastases
UA95930C2 (uk) Інгібітори цистеїнпротеаз, фармацевтична композиція, яка їх містить, та їх терапевтичне застосування
MY139221A (en) Cathepsin cysteine protease inhibitors
TH70460A (th) สิ่งที่รวมกันของตัวที่ขัดขวางคะเทพซินเค (Cathepsin K) และบีสฟอสโฟเนท ในการทำการบำบัดมีแทสทาซีสของกระดูกการเติบโตของเนื้องอก และการเสียกระดูกที่ถูกชักนำโดยเนื้องอก

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application